FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB | ΛDE | | ۱/۸ |
|-------|-----|------|-----|
| CHVID | APE | ~~() | VA |

| OMB Number: | 3235-0104 |
|--------------------------|-----------|
| Estimated average burden | |
| hours per response: | 0.5 |

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* GORDON MICHAEL S | | Statement (Month/Day/Year) 12/25/2023 4. R | 3. Issuer Name and Ticker or Trading Symbol ProMIS Neurosciences Inc. [PMN] | | | | | |
|--|---------|--|---|---|---------------------------------|---|---|--|
| (Last) (First) (Middle) C/O JDJFOS, 2 OLIVER STREET, SUITE 905 | | | Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | 5. If Amendment, Date of Original Filed (Month/Day/Year) | | |
| | | | Director Officer (give title below) | X | 10% Owner Other (specify below) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person | | |
| (Street) BOSTON | MA | 02109 | | | | | Form filed by More than One Reporting Person | |
| (City) | (State) | (Zip) | | | | | | |

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | l ' |
|---------------------------------|--|--|-----------------------------------|
| Common Shares, no par value | 1,110,513 | I | By Title 19 Promis ⁽¹⁾ |
| Common Shares, no par value | 48,333 | I | By Title 19 Acies ⁽²⁾ |

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | | (D) or | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|--------------------|---|-------------------------------------|------------------------------------|----------------------------|---|
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | Price of Derivative Security | Indirect (I) (Instr. 5) | |
| Warrants to Purchase Common Shares, no par value | (3) | (3) | Common Shares | 51,562 | (3) | I | By Title 19 Promis ⁽¹⁾ |
| Warrants to Purchase Common Shares, no par value | (4) | (4) | Common Shares | 26,597 | (4) | I | By Title 19 Promis ⁽¹⁾ |
| Warrants to Purchase Common Shares, no par value | (5) | (5) | Common Shares | 797,872 | (5) | I | By Title 19 Promis ⁽¹⁾ |
| Series 2 Preferred Shares, no par value | (6) | (6) | Common Shares | 500,000 | (6) | I | By Title 19 Promis ⁽¹⁾ |

Explanation of Responses:

- 1. By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.
- 2. By Title 19 Acies, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.
- 3. Consists of 51,562 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of \$0.21 per whole warrant. These warrants are currently exercisable and expire on August 24,
- 4. Consists of 26,597 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of \$7.50 per whole warrant. These warrants are part of Units, each consisting of one Common Share and one-quarter of one warrant to purchase one Common Share. The purchase price for each Unit was \$5.40. These warrants are currently exercisable and expire on April 11, 2028, the fifth anniversary of the date the warrants first became exercisable.
- 5. Consists of 797,872 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of \$1.75 per whole warrant beginning February 23, 2024. These warrants expire on February 23, 2029, the fifth anniversary of the date the warrants first become exercisable.
- 6. The Series 2 Preferred Shares are nonvoting and noninterest bearing and are currently convertible at a 1:1 ratio into Common Shares at the option of the holder. The Series 2 Preferred Shares will involuntarily convert into Common Shares upon cumulative qualified equity financing in excess of \$14 million.

/s/ Michael S. Gordon

** Signature of Reporting Person

Date

12/27/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.